PTN Palatin Technologies Inc.

0.63
-0.00  -1%
Previous Close 0.63
Open 0.63
Price To book -5.22
Market Cap 95730331
Shares 152,801,806
Volume 1,297,780
Short Ratio 13.21
Av. Daily Volume 1,592,981

SEC filingsSee all SEC filings

  1. 8-K - Current report 171081411
  2. 8-K - Current report 171073197
  3. 8-K - Current report 17900393
  4. 8-K - Current report 17847241
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 17844578

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released November 1, 2016. NDA filing due 1Q 2018.
Rekynda (Bremelanotide)
Female sexual dysfunction (FSD)
Phase 2 planned for 1H 2017
PL-3994
Heart failure

Latest News

  1. Palatin Technologies Announces Appointment of Anthony M. Manning, Ph.D. to Board of Directors
  2. Palatin Technologies Announces Signing of Licensing Agreement with Fosun Pharma Rights to Bremelanotide in China and Other Selected Territories
  3. Edited Transcript of PTN earnings conference call or presentation 16-May-17 3:00pm GMT
  4. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on May 16, 2017
  5. Palatin Technologies, Inc. to Report Third Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on May 16, 2017
  6. Palatin Technologies to Present at The MicroCap Conference on April 4th at 1:00 PM ET in New York City at the Essex House
  7. Palatin Technologies Receives Notice of Allowance on Bremelanotide Methods of Use Patent for Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women
  8. Palatin Technologies To Present At The 29th Annual ROTH Conference
  9. Palatin Technologies, Inc. :PTN-US: Earnings Analysis: Q2, 2017 By the Numbers
  10. AMAG Pharmaceuticals Inks $60M Drug Deal
  11. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on February 9, 2017
  12. Palatin Technologies Announces Closing of License Agreement with AMAG Pharmaceuticals for North American Rights to Rekynda™
  13. Palatin (PTN) Sees Hammer Chart Pattern: Time to Buy?
  14. Palatin Technologies to Hold Call Following Closing of Licensing Agreement for North American Rights to Rekynda™
  15. AMAG Pharmaceuticals, Inc. (AMAG), Palatin Technologies, Inc. (PTN) In Licensing Deal
  16. AMAG, Palatin Ink Deal to Focus on Female Sexual Disorder
  17. Why AMAG Pharmaceuticals, Inc. Is Falling Today